Your Medication Isn't Working. Your Genes May Be Why.

CYP2C19 is a cytochrome P450 enzyme that your liver uses to break down a wide range of medications, including clopidogrel (Plavix), a blood thinner used after heart stents; proton pump inhibitors like omeprazole; and several antidepressants including sertraline and escitalopram. If this enzyme works properly, it converts these drugs from inactive forms into active compounds that can do their job. It’s the rate-limiting step in treatment.

Here’s the problem: genetic variants like *2 and *3 slow this enzyme down dramatically. People carrying these variants, roughly 2 to 15% depending on ancestry, are classified as poor metabolizers. What that means in practical terms is that medications aren’t being activated properly. Clopidogrel is particularly dangerous for poor metabolizers; your body can’t convert it into its active form, so the blood thinner never actually prevents clots. You’re taking a medication under the assumption it’s protecting your heart, but genetically, it’s doing nothing.

If you’re a poor metabolizer of CYP2C19, antidepressants hit you harder and faster. Doses that are therapeutic for most people might make you feel sedated, foggy, or emotionally blunted. You mention this to your doctor, they lower the dose, and now you’re under-treated. You feel stuck between two bad options. Meanwhile, if you’re an ultra-rapid metabolizer (variant *17), the opposite happens: standard doses barely touch your symptoms, so you keep escalating, and your doctor thinks you need a higher dose than you actually do.

CYP2D6 is the busiest cytochrome P450 enzyme in your body. It metabolizes antidepressants like venlafaxine and fluoxetine, antipsychotics, beta-blockers, opioids, and codeine. It’s the main reason some medications work brilliantly for some people and cause nightmarish side effects in others. The genetic variation here is dramatic: some people have zero functional copies, some have one, some have two, and some have duplications that give them three or four.

Genetic variants like *4, *10, and *17 reduce enzyme activity. Poor metabolizers (roughly 7 to 10% of European ancestry) have significantly reduced ability to break down these drugs. If you take codeine and you’re a poor metabolizer, codeine never converts to morphine, so you get no pain relief and experience the side effects of an active drug your body can’t use. For antidepressants, poor metabolizers accumulate toxic levels even at standard doses, leading to dizziness, tremor, sexual dysfunction, or emotional flatness. Ultra-rapid metabolizers, who have gene duplications, are the opposite: they burn through medications so quickly that standard doses feel like placebos.

This gene explains why one person thrives on 50 mg of sertraline and another becomes a zombie on the same dose. It explains why some people feel nothing from their pain medication, or why some people have intolerable side effects that another person never experiences. Your CYP2D6 status determines whether you need half the standard dose, the standard dose, or twice the standard dose to get the same therapeutic effect.

CYP2C9 metabolizes warfarin (Coumadin), a blood thinner used for atrial fibrillation and clotting disorders. It also breaks down NSAIDs like ibuprofen and naproxen, and some statins. Warfarin is one of the most dangerous drugs in the pharmacopeia if you get the dose wrong, because the margin between therapeutic and bleeding is narrow. Your doctor has to monitor your INR (international normalized ratio) regularly to keep you in the right range. But here’s what most doctors don’t realize: your CYP2C9 status predicts your warfarin dose more accurately than any blood test.

Variants like *2 and *3 slow this enzyme down. Poor metabolizers, roughly 5 to 10% of European ancestry, cannot clear warfarin efficiently. Standard warfarin doses designed for average metabolizers can cause dangerous bleeding in poor metabolizers because the drug accumulates to higher levels than expected. These people need significantly lower maintenance doses, and they get there only through trial and error and INR monitoring, which takes months. Meanwhile, they’re at risk. Ultra-rapid metabolizers need higher doses to achieve the same anticoagulation.

If you’re a poor metabolizer of CYP2C9, every time your dose is adjusted, it takes weeks to see the effect. You have to keep getting blood tests. Your INR might swing wildly. You feel like your anticoagulation is out of control. The reality is your genes are processing the drug differently than the dosing guidelines assumed.

VKORC1 isn’t an enzyme that metabolizes drugs. It’s the target of warfarin. VKORC1 codes for vitamin K epoxide reductase, an enzyme involved in the vitamin K cycle that produces the clotting factors your blood needs. Warfarin works by inhibiting this enzyme, which stops your blood from clotting. The VKORC1 gene itself has a variant called -1639G>A that affects how sensitive you are to warfarin, independent of how fast you metabolize it.

People carrying the A allele of this variant, roughly 40% of European ancestry, have reduced vitamin K recycling. They’re intrinsically more sensitive to warfarin. The same dose that produces mild anticoagulation in a G/G person can produce dangerous bleeding in an A/A person. This isn’t about drug metabolism at all. It’s about your baseline biology. Your body’s vitamin K cycle is wired to be more responsive to warfarin inhibition. Even if your CYP2C9 is normal and you metabolize warfarin perfectly, your VKORC1 status still determines how much drug effect you get per milligram of warfarin you take.

If you’re an A/A carrier, you might feel confused about your warfarin dose because it seems to be wildly different from your friends’ doses. You think maybe you’re just more sensitive to medication in general. The truth is your VKORC1 variant is making your vitamin K pathway more responsive to warfarin inhibition. It’s a genetic truth, not a weakness.

SLCO1B1 codes for a transporter protein in your liver cells that pulls statins from the bloodstream into the liver, where they do their job of lowering cholesterol. This transporter is like a door. If the door works well, statins get into liver cells efficiently. If the door is broken, statins stay in your bloodstream and muscle tissue longer than intended. This matters because statins can cause muscle pain, weakness, and breakdown (rhabdomyolysis) if they accumulate outside the liver.

A specific variant, rs4149056 (C allele), roughly 15% of the population, reduces how well this transporter works. People carrying this variant, classified as SLCO1B1 intermediate or poor carriers, have reduced hepatic uptake of statins. Simvastatin and atorvastatin accumulate to higher levels in the bloodstream and muscle tissue, increasing the risk of myopathy and statin-related muscle pain. Your doctor might think you’re having statin side effects and blame the medication class in general, but the real problem is this one transporter gene variant that causes systemic statin accumulation.

If you have this variant and you take simvastatin, you’re at substantially higher risk of muscle pain and weakness. If you’re SLCO1B1 intermediate or poor, you might tolerate a different statin like rosuvastatin or pravastatin much better, because they don’t depend as heavily on this transporter. You might take the exact same dose of rosuvastatin with no side effects, while simvastatin at half the dose makes your legs hurt. That’s SLCO1B1.

TPMT (thiopurine S-methyltransferase) metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine. These drugs are immunosuppressants used for severe autoimmune diseases, inflammatory bowel disease, and some leukemias. They work by suppressing your immune system, which is what you need when your immune system is attacking itself. But they’re dangerous. They can cause bone marrow suppression, liver toxicity, and pancreatitis if you accumulate too much active drug in your body.

TMPT poor metabolizers, roughly 0.3% of the population but higher in certain ancestries, cannot break down these drugs efficiently. Standard doses designed for normal metabolizers cause these drugs to accumulate to toxic levels, leading to severe bone marrow suppression, life-threatening infections, and death if not caught. Poor metabolizers need dramatically lower doses, sometimes 5 to 10% of the standard dose, to get a safe and therapeutic effect. Ultra-rapid metabolizers, on the opposite end, might not get any immunosuppressive benefit from standard doses.

If you’re a poor metabolizer and your doctor prescribes standard-dose azathioprine without genetic testing, you’re at serious risk. You’ll start having bruising, infections, mouth sores, and severe fatigue as your bone marrow shuts down. By the time your bloodwork shows the problem, you might already be in the hospital. This is one of the clearest cases where pharmacogenomics testing before starting the medication is literally lifesaving.